Pfizer Inc. (PFE) Stock Analysis
Latest ClaritX AI analysis ·
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of
| Metric | Value |
|---|---|
| Price | $28.28 |
| Market cap | $161.2B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ClaritX AI score | 86/100 |
| Price/Book | 1.89 |
| Dividend yield | 6.08% |
| Beta | 0.28 |
AI verdict
Pfizer Inc. (PFE) has rapidly evolved from a passive, deep-value income trap into a highly dynamic, activist-driven turnaround play, offering investors a rare combination of a massively secure dividend yield and imminent structural catalysts. Currently trading at $28.28, the equity sits a mere 3.18% below its 52-week high of $29.21. Maintaining this exceptionally tight proximity to the yearly peak alongside an extraordinarily low beta of exactly 0.276 mathematically confirms that the stock is acting as a heavily insulated, non-correlated safe harbor. This exceptionally low beta means Pfizer is largely immune to systemic macroeconomic volatility and tech-sector rotations, while the price action indicates methodical, aggressive institutional accumulation rather than retail euphoria. Fundamentally, the anxieties regarding the post-2029 patent cliff and Bourla's historic M&A spending are actively being addressed by the arrival of activist investor Starboard Value. Their $1 billion stake is expected to ruthlessly enforce capital discipline and R&D optimization, effectively capping downside risk. Crucially, the 6.08% dividend yield remains completely mathematically secured by a stabilized Free Cash Flow of $1.927 per share, proving the enterprise can effortlessly fund its $1.72 obligation independent of distorted GAAP net income metrics. Bolstered by staggering multi-quarter insider buy volume and recent analyst upgrades, Pfizer offers an unparalleled entry point for investors see
What this score has been worth
ClaritX scores PFE 86 out of 100, ranking it #28 among stock in the live ClaritX ranking (snapshot 2026-10-16).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +2.0% with a 59% win rate, -1.8pp against the S&P 500. That is a measured tendency across many names, not a forecast for PFE — roughly 41% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.